Go to page
 

Bibliographic Metadata

Title
Accuracy of novel diagnostic biomarkers for hepatocellular carcinoma: An update for clinicians
AuthorMikulits, Wolfgang ; Reichl, Patrick
Published in
Oncology Reports, Athens, 2016, Vol. 36, Issue 2, page 613-625
PublishedAthens : Spandidos Publications, 2016
LanguageEnglish
Document typeJournal Article
Keywords (EN)diagnostic biomarker / hepatocellular carcinoma / alpha-fetoprotein / des-gamma-carboxyprothrombin / annexin a2 / soluble axl / thioredoxin / minichromosome maintenance / monocyte chemoattractant protein-1 / epidermal-growth-factor / human gastric-cancer / squamous-cell carcinoma / beta-binding-protein / latent-tgf-beta / alpha-fetoprotein / annexin-ii / early-stage / thioredoxin system
Project-/ReportnumberP 25356-B13
ISSN1021-335X
URNurn:nbn:at:at-ubmuw:3-1326 Persistent Identifier (URN)
DOI10.3892/or.2016.4842 
Restriction-Information
 The work is publicly available
Files
Accuracy of novel diagnostic biomarkers for hepatocellular carcinoma: An update for clinicians [0.38 mb]
Links
Reference
Classification
Abstract (English)

Hepatocellular carcinoma (HCC) is the most common liver malignancy and a leading cause of cancer-related mortality worldwide. Accurate detection and differential diagnosis of early HCC can significantly improve patient survival. Currently, detection of HCC in clinical practice is performed by diagnostic imaging techniques and determination of serum biomarkers, most notably alpha-fetoprotein (AFP), fucosylated AFP and des-gamma-carboxyprothrombin. However, these methods display limitations in sensitivity and specificity, especially with respect to early stages of HCC. Recently, high-throughput technologies have elucidated many new pathways involved in hepatocarcinogenesis and have led to the discovery of a plethora of novel, non-invasive serum biomarkers. In particular, the combination of AFP with these new candidate molecules has yielded promising results. In this review, we aimed at recapitulating the most recent (2013-2015) developments in HCC biomarker research. We compared promising novel diagnostic serum protein biomarkers, such as annexin A2, the soluble form of the receptor tyrosine kinase Axl and thioredoxin, as well as their combinations with AFP. High diagnostic performance (area under the curve >0.75) as shown by threshold-independent receiver operating characteristic curve analysis was a prerequisite for inclusion in this review. In addition, we discuss the role and potential of microRNAs in HCC diagnosis and associated methodological challenges.

Stats
The PDF-Document has been downloaded 4 times.
License
CC-BY-NC-ND-License (4.0)Creative Commons Attribution - NonCommercial - NoDerivatives 4.0 International License